



26 **Abstract**

27 We assessed the pharmacokinetics of favipiravir (FPV) in adults with symptomatic SARS-CoV-2  
28 infection without pneumonia in Thailand. FPV dosing was 1800 mg twice-daily on day 1, then 800 mg  
29 twice-daily for 14 days. Eight subjects (7 female), median (range) age 39 (19-53) years and BMI 27.9  
30 (18.0-33.6) were included. Inter-subject variability was high but all achieved minimum plasma  
31 concentrations ( $C_{\min}$ ) above  $EC_{50}$  (9.7 mg/L). FPV was well tolerated; 1 subject stopped prematurely due  
32 to rash.

33

34 **Key words:** Favipiravir, COVID-19, Thai adults, pharmacokinetic

## 35 **Introduction**

36 Favipiravir (FPV) is a pyrazine carboxamide derivative that has recently been repurposed to treat mild-to-  
37 moderate cases of COVID-19 (1,2). Preliminary studies have demonstrated its capacity to competitively  
38 inhibit the replication of SARS-CoV-2 *in-vitro* (3-5) and possibly control viral progression, promote viral  
39 clearance, as well as improve clinical outcomes *in-vivo* (5, 6).

40  
41 FPV is a prodrug (T-705) that is intracellularly metabolised through ribosylation into its active form (T-  
42 705-RTP). Viral RNA-dependant RNA polymerase (RdRp) recognises this active form as a purine-base  
43 analogue and incorporates it into nascent viral RNA whereby it exerts its antiviral activity (1, 2, 5-7). FPV  
44 is primarily metabolised by hepatic aldehyde oxidase, and partially by xanthine oxidase, to a hydroxylated  
45 inactive metabolite (T-705M1) that is excreted in the urine (4, 7, 8).

46  
47 The recommended FPV dosing regimen for the treatment of COVID-19 in Thailand is 1800 mg twice-  
48 daily for the first day, and then 800 mg twice-daily for a total duration of 5-14 days (5). While numerous  
49 studies have explored the clinical effects of such dosing regimens, few studies have assessed its  
50 pharmacokinetics, and no studies have been performed in the Thai population (9, 10). It is important to  
51 characterise the impact of regional and ethnic difference on the pharmacokinetic profile to ensure  
52 optimised dosing for the viral variants circulating in the region (9). Our aim was to investigate the  
53 pharmacokinetics of FPV in mild cases of COVID-19 without pneumonia within a Thai population.

## 54 **Methods**

55 Here we report the results of a pharmacokinetic sub-study of FPV nested within a prospective randomized  
56 clinical trial of adults with symptomatic SARS-CoV-2 infection without pneumonia. Enrolled subjects  
57 were randomised to receive supportive symptomatic care with or without FPV. The FPV dosing regimen  
58 was 1800 mg twice-daily on the first day, and then 800 mg twice-daily for 5-14 days or until viral  
59 clearance. Subjects receiving other medication with reported antiviral activity against SARS-CoV-2 were  
60 excluded. Pharmacokinetic assessments were proposed to subjects receiving FPV. This study was  
61 approved by the Siriraj Institutional Review Board (approval no. Si 434/2020) and registered at  
62 [Thaicalinicaltrials.org](https://www.clinicaltrials.gov/ct2/show/study?term=TCTR20200514001&rank=1) (No. TCTR20200514001).

63

### 64 *Pharmacokinetic Assessments*

65 Blood samples were drawn pre-dose, and 1-hour after FPV administration on days 1, 2, 3, 4, 5, 7, and 14.  
66 Plasma proteins were precipitated with ethanol (1:4) and the supernatant stored at -20°C until analyses. T-  
67 705 and T-705M1 concentrations were quantified using a validated high performance liquid  
68 chromatography-UV assay, with a calibration range of 0.1 to 50 mg/L.

69

## 70 **Results**

71 Eight patients (7 females) were included, median (range) age was 39 (19-53) years, BMI was 27.9 (18.0-  
72 33.6), 3 patients (37.5%) had underlying diseases, and none developed pneumonia or experienced disease  
73 progression. Subjects No. 1 and 3-5 were treated with FPV for 14 days, while subjects No. 6-8 were  
74 treated for 7 days. Subject No. 2 dropped out on day 4 of treatment due to an erythematous skin rash.  
75 Individual plasma concentrations versus time curves for T-705 and T-705M1 after the first dose of FPV  
76 are shown in Figure 1. Initial pre-dose T-705 concentrations for subjects No. 4 and 5 indicated they had  
77 received a dose of FPV before PK assessment.

78

79 Minimum plasma concentration levels ( $C_{\min}$ ) of T-705 were above the reported  $EC_{50}$  for SARS-COV-2  
80 (9.7 mg/L) for all subjects, except for subject No. 6 after their first dose (8.6 mg/L). The  $C_{\min}$  and  $C_{\max}$  of  
81 T-705 ranged from 12.1-132.2 mg/L and 14.5-201.2 mg/L, respectively, and was found to decreased  
82 overtime.  $C_{\min}$  and  $C_{\max}$  of T-705M1 ranged from 1.6-6.7 mg/L and 2.0-24.8 mg/L, respectively, but  
83 remained relatively stable overtime. Inter-subject variability was high, with a coefficient of variation  
84 (CV) of 37-74% for T-705 and 12-62% for T-705M1.

85

## 86 Discussion

87 We evaluated FPV plasma concentrations in adults with mild COVID-19 that did not require oxygen  
88 supplementation. FPV plasma concentrations with the currently recommended FPV dosing regimen in  
89 Thailand [1800 mg twice-daily (9 tablets per dose) on day 1, followed by 800 mg twice-daily (4 tablets  
90 per dose) until the end of treatment] provided concentrations above the reported  $EC_{50}$ .

91

92 Favipiravir loading doses studied have ranged from 400-6000 mg, split into 2-3 doses per day (11). A  
93 1600 mg twice-daily dose on day 1, followed by 600 mg twice-daily on days 2-5 achieve trough  
94 concentrations between 20-60 mg/L after 12 hours (12). The large loading dose of FPV used in our study  
95 was reported to rapidly reach minimum target concentrations of 40-80 mg/L, and the large difference  
96 between its  $EC_{50}$  of 61.88  $\mu\text{M}$  (9.72 mg/L) and half-cytotoxic concentration ( $CC_{50}$ ) of >400  $\mu\text{M}$  (62.83  
97 mg/L) provides a wide therapeutic range (3,5,11).

98

99 Some controversy remains regarding the  $EC_{50}$  of FPV for SARS-CoV-2. Some studies have reported  
100 similar values to our study (9,12); while others failed to identify inhibition of SARS-CoV-2 below 100  
101  $\mu\text{M}$  (15.71 mg/L) *in-vitro* (15), or found only 50% virus inhibition at this concentration (16). All of the  
102 adults in our study achieved T-705 concentrations above our target  $EC_{50}$  of 9.7 mg/L. The high  
103 interpatient variability observed is likely a result of the multiple intrinsic and external factors that can  
104 impact the pharmacokinetic profile of FPV (9). For example, the potential impact of pharmacogenomics

105 on FPV clearance in different populations is highlighted by the significantly higher FPV plasma  
106 concentrations in Japanese populations compared to patients in the United States (7), and decreased  
107 exposures in African and American patients compared to Chinese patients (18). While the T-705 plasma  
108 concentration varied between patients, the overall concentrations observed in our study remained within  
109 target ranges. Favipiravir was well tolerated, except for one patient who experienced a cutaneous rash and  
110 discontinued treatment. Of note, this participant had relatively high FPV concentrations (99.7-201.2  
111 mg/L) and low BMI (18.3). None of the patients' clinical outcomes deteriorated during FPV treatment  
112 but a larger population of mild COVID-19 cases is needed to confirm this observation.

113  
114 A limitation of this study was the ability to associate clinical or virologic outcomes with FPV drug  
115 exposure. Overall, this study provides novel data on the pharmacokinetics of FPV and its metabolite in  
116 adults with symptomatic SARS-CoV-2 infection without pneumonia and can help to guide dosing  
117 recommendations.

118  
119 **Acknowledgements**

120 We would like to thank the National Centre for Global Health and Medicine, Japan and FUJIFILM  
121 Toyama Chemical Co., Ltd. We are also thankful for the support from the National Institute of Health,  
122 Thailand.

123  
124 **Data availability statement**

125 Data are available upon request.  
126

127 **Funding**

128 This work was supported by the National Research Council of Thailand (Grant Number: 63-088) and the  
129 Siriraj Research and Development Fund, Faculty of Medicine Siriraj Hospital, Mahidol University (Grant  
130 Number: (IO) R016434001).

131

132 **Transparency declarations**

133 None to declare

134 **References**


- 135 1. Seneviratne SL, Abeysuriya V, De Mel S, De Zoysa I, Niloofa R. 2020. Favipiravir in COVID-19.  
136 *IJPSAT* 19:143–145.
- 137 2. Furuta Y, Komeno T, Nakamura T. 2017. Favipiravir (T-705), a broad spectrum inhibitor of viral  
138 RNA polymerase. *Proc Jpn Acad Ser B Phys Biol Sci* 93:449–463.
- 139 3. Wang M, Cao R, Zhang L, Yang X, Liu J, Xu M, Shi Z, Hu Z, Zhong W, Xiao G. 2020. Remdesivir  
140 and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.  
141 *Cell Res* 30:269-271.
- 142 4. Eroglu E, Toprak C. 2021. Overview of Favipiravir and Remdesivir treatment for COVID-19. *Int J*  
143 *Pharm Sci Res* 12:1950–7.
- 144 5. Joshi S, Parkar J, Ansari A, Vora A, Talwar D, Tiwaskar M, Patil S, Barkate H. 2021. Role of  
145 favipiravir in the treatment of COVID-19. *Int J Infect Dis* 102:501–508.
- 146 6. Doi Y, Hibino M, Hase R, Yamamoto M, Kasamatsu Y, Hirose M, Mutoh Y, Homma Y, Terada M,  
147 Ogawa T, Kashizaki F, Yokoyama T, Koba H, Kasahara H, Yokota K, Kato H, Yoshida J, Kita T,  
148 Kato Y, Kamio T, Kodama N, Uchida Y, Ikeda N, Shinoda M, Nakagawa A, Nakatsumi H,  
149 Horiguchi T, Iwata M, Matsuyama A, Banno S, Koseki T, Teramachi M, Miyata M, Tajima S, Maeki  
150 T, Nakayama E, Taniguchi S, Lim C, Saijo M, Imai T, Yoshida H, Kabata D, Shintani A, Yuzawa Y,  
151 Kondo M. 2020. A Prospective, Randomized, Open-Label Trial of Early versus Late Favipiravir  
152 Therapy in Hospitalized Patients with COVID-19. *Antimicrob Agents Chemother* 64.
- 153 7. Du YX, Chen XP. Favipiravir: 2020. Pharmacokinetics and Concerns About Clinical Trials for 2019-  
154 nCoV Infection. *Clin Pharmacol Ther* 108:242–247.
- 155 8. FUJIFILM Toyama Chemical Co. L. Notice of The New Drug Application Approval of “AVIGAN®  
156 Tablet 200mg” in Japan for the Anti-influenza Virus Drug.  
157 [https://www.cdc.gov.tw/File/Get/ht8jUiB\\_MI-aKnIwstzwvw](https://www.cdc.gov.tw/File/Get/ht8jUiB_MI-aKnIwstzwvw).
- 158 9. Ison MG, Scheetz MH. 2021. Understanding the pharmacokinetics of Favipiravir: Implications for  
159 treatment of influenza and COVID-19. *EBioMedicine* 63:103204.



- 160 10. Irie K, Nakagawa A, Fujita H, Tamura R, Eto M, Ikesue H, Muroi N, Fukushima S, Tomii K,  
161 Hashida T. 2021. Population pharmacokinetics of favipiravir in patients with COVID-19. *CPT*  
162 *Pharmacometrics Syst Pharmacol* 10:1161–1170.
- 163 11. Pilkington V, Pepperrell T, Hill A. 2020. A review of the safety of favipiravir – a potential treatment  
164 in the COVID-19 pandemic? *J Virus Erad* 6:45–51.
- 165 12. Irie K, Nakagawa A, Fujita H, Tamura R, Eto M, Ikesue H, Muroi N, Tomii K, Hashida T. 2020.  
166 Pharmacokinetics of Favipiravir in Critically Ill Patients With COVID-19. *Clin Transl Sci* 13:880–  
167 885.
- 168 13. Manabe T, Kambayashi D, Akatsu H, Kudo K. 2021. Favipiravir for the treatment of patients with  
169 COVID-19: a systematic review and meta-analysis. *BMC Infect Dis* 21:489.
- 170 14. Department of Disease Control. Guidelines for clinical practice, diagnosis, treatment and prevention  
171 of healthcare-associated infection in response to patients with COVID-19 infection.  
172 [https://ddc.moph.go.th/viralpneumonia/eng/file/guidelines/g\\_CPG.pdf](https://ddc.moph.go.th/viralpneumonia/eng/file/guidelines/g_CPG.pdf).
- 173 15. Choy K, Wong A, Kaewpreedee P, Sia S, Chen D, Hui K, Chu D, Chan M, Cheung P, Huang X,  
174 Peiris M, Yen H. 2020. Remdesivir, lopinavir, emetine, and homoharringtonine inhibit SARS-CoV-2  
175 replication in vitro. *Antiviral Res* 178:104786.
- 176 16. Lou Y, Liu L, Yao H, Hu X, Su J, Xu K, Luo R, Yang X, He L, Lu X, Zhao Q, Liang T, Qiu Y.  
177 2021. Clinical Outcomes and Plasma Concentrations of Baloxavir Marboxil and Favipiravir in  
178 COVID-19 Patients: An Exploratory Randomized, Controlled Trial. *Eur J Pharm Sci* 157:105631.
- 179 17. Takahashi T, Luzum JA, Nicol MR, Jacobson PA. 2020. Pharmacogenomics of COVID-19  
180 therapies. *NPJ Genom Med* 5:35.
- 181 18. Pertinez H, Rajoli RKR, Khoo SH, Owen A. 2021. Pharmacokinetic modelling to estimate  
182 intracellular favipiravir ribofuranosyl-5'-triphosphate exposure to support posology for SARS-CoV-  
183 2. *J Antimicrob Chemother* 76:2121–2128.

- 184 19. Kaur R, Charan J, Dutta S, Sharma P, Bhardwaj P, Sharma P, Lugova H, Krishnapillai A, Islam S,  
185 Haque M, Misra S. 2020. Favipiravir Use in COVID-19: Analysis of Suspected Adverse Drug  
186 Events Reported in the WHO Database. *Infect Drug Resist* 13:4427–4438.

187 **Figure Legend**



188  
189 **Figure 1.** Individual plasma concentration of T-705 and T-705M1 for (a) Subject No. 1, female with BMI  
190 of 30.1 within age range of 30-35 years, (b) Subject No. 2, female with BMI of 18.3 within age range of  
191 35-40 years, (c) Subject No. 3, female with BMI of 33.6 within age range of 40-45 years, (d) Subject No.  
192 4, female with BMI of 30 within age range of 25-30 years, (e) Subject No. 5, female with BMI of 27.5  
193 within age range of 45-50 years, (f) Subject No. 6, male with BMI of 26.9 within age range of 50-55  
194 years, (g) Subject No. 7, female with BMI of 28.2 within age range of 35-40 years, and (h) Subject No. 8,  
195 female with BMI of 18 within age range of 15-20 years. The dash line represents an EC<sub>50</sub> of 9.7 mg/L.

196